What is a Statement of Grant of Protection in international design applications?

A Statement of Grant of Protection is a formal notification sent by the United States Patent and Trademark Office (USPTO) to the International Bureau of the World Intellectual Property Organization (WIPO) after a patent is issued on an international design application designating the United States. This statement confirms that protection has been granted for the…

Read More

What was the standard for granting an inter partes reexamination request?

The standard for granting an inter partes reexamination request changed over time. Initially, under 35 U.S.C. 312(a), the standard was whether “a substantial new question of patentability affecting any claim of the patent concerned is raised by the request,” known as the SNQ standard. However, during the one-year transition period (September 16, 2011 to September…

Read More

What standards are used to evaluate reexamination requests?

The standards used to evaluate reexamination requests have changed over time. For requests filed: Prior to September 16, 2011: The standard was “substantial new question of patentability” (SNQ). From September 16, 2011 to September 15, 2012: The standard was “reasonable likelihood that requester will prevail” (RLP). The MPEP provides specific language for each standard: “No…

Read More

What is the standard term for a utility patent?

The standard term for a utility patent is 20 years from the filing date of the earliest application to which the patent claims priority. This is known as the “twenty-year term.” As stated in the MPEP, For applications filed on or after June 8, 1995, Section 532(a)(1) of the Uruguay Round Agreements Act (Public Law…

Read More

What are the standard nucleotides not considered as “Modified Nucleotides” according to MPEP 2412.03(e)?

MPEP 2412.03(e) provides a list of standard nucleotides that are not considered “Modified Nucleotides”. These are: deoxyadenosine 3′-monophosphate deoxyguanosine 3′-monophosphate deoxycytidine 3′-monophosphate deoxythymidine 3′-monophosphate adenosine 3′-monophosphate guanosine 3′-monophosphate cytidine 3′-monophosphate uridine 3′-monophosphate These nucleotides represent the standard DNA (first four) and RNA (last four) building blocks. Any nucleotide that is not one of these standard…

Read More

What is the standard for indefiniteness in patent claims?

The standard for indefiniteness in patent claims is based on the “reasonable certainty” test established by the Supreme Court. As stated in MPEP 2173.02: “A claim is indefinite when it contains words or phrases whose meaning is unclear. In re Packard, 751 F.3d 1307, 1314 (Fed. Cir. 2014). The test for definiteness under 35 U.S.C.…

Read More